Healthcare Whitepaper Accelerating adoption of decentralized trials in a post COVID-19 era The impact of COVID-19 on the operations of clinical trials across the globe is grave. It is giving organizations a reason to embrace technology like never before and organizations are definitely making the shift. Let’s take a look at these numbers - 88% of global pharmaceutical companies and CROs are investing in remote trial monitoring solutions. Enterprise contact center call volumes are jumping over 800% from normal levels during the COVID-19 trials. Pharma and clinical research organizations are adopting technological interventions to ensure protocol adherence. And why not? Technology can help with seamless virtual trials and patient engagement in these unprecedented times. It can enable faster recruitment of patients, ensure their adherence to medication and retain them successfully by providing support through digital means. Virtual is set to become the norm in clinical trials and real-world studies. The market size for virtual clinical trials is set to grow at a CAGR of 5.1% from 2020 to 2027 with COVID–19 expediting the process. Want to know more? Download the white paper and find answers to all your technology-related queries for clinical trials.